Compare BTCT & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTCT | IMRN |
|---|---|---|
| Founded | 2006 | 1994 |
| Country | Singapore | Australia |
| Employees | 26 | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4M | 9.6M |
| IPO Year | N/A | 2016 |
| Metric | BTCT | IMRN |
|---|---|---|
| Price | $0.52 | $1.06 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 319.0K | 40.5K |
| Earning Date | 05-29-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $283.35 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $0.68 |
| 52 Week High | $3.12 | $2.38 |
| Indicator | BTCT | IMRN |
|---|---|---|
| Relative Strength Index (RSI) | 25.18 | 42.55 |
| Support Level | N/A | $0.96 |
| Resistance Level | $1.21 | $1.24 |
| Average True Range (ATR) | 0.06 | 0.09 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 1.12 | 7.48 |
BTC Digital Ltd is the ledger technology that underlies bitcoin and other cryptocurrencies, based in the U.S., with a focus on bitcoin mining. A blockchain is a decentralized, distributed, and encrypted digital public ledger that stores information in a secure, verifiable, and permanent way. The company also generates revenue through the resale of mining machines, mining machine rental, and miner hosting services.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.